Department of Internal Medicine, John Hopkins Hospital, Baltimore, MD 21287, USA.
Department of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA.
Oncotarget. 2023 Sep 28;14:843-857. doi: 10.18632/oncotarget.28514.
UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.
UDP-葡萄糖-6-脱氢酶(UGDH)是一种胞质六聚体酶,可将 UDP-葡萄糖转化为 UDP-葡萄糖醛酸(UDP-GlcUA),这是激素和外源性代谢物以及细胞外基质前体生成中的关键反应。在这篇综述中,我们将 UGDH 分类为多种癌症类型中肿瘤进展的分子标志物,描述其在关键的经典癌症信号通路中的作用,并确定抑制 UGDH、其底物及其下游产物的方法。因此,我们将 UGDH 定位为一种有望成为肿瘤学中潜在预后标志物和癌症生物学中治疗靶点的酶。